SCHEMBL10243910

SCHEMBL10243910

CN1C(=O)CCCc2cc(Nc3ncc(C(N)=O)c(NC4CC4)n3)ccc21

nearest known ligand 0.66

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SYK P43405 16/20 0.66
INSR P06213 4/20 0.66
MET P08581 1/20 0.66
ALK Q9UM73 3/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735166 0.93 SYK (0.71) SYKINSRMET
SCHEMBL15161229 0.90 SYK (0.66) SYK
Carbamic Acid SCHEMBL16966116 0.85 INSR (0.77) SYKINSRMETALK
SCHEMBL10242872 0.82 CHEK1 (0.71) SYK
SCHEMBL737718 0.81 SYK (0.87) SYK
SCHEMBL10242871 0.81 SYK (0.72) SYK
SCHEMBL10243924 0.80 SYK (0.79) SYK
SCHEMBL885749 0.80 INSR (1.00) SYKINSRMETALK
SCHEMBL1354459 0.80 SYK (1.00) SYK
SCHEMBL736576 0.79 SYK (1.00) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501944-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 SYK 1/4885INSR 3211/4885MET 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.